Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Escherichia coli/Shigella oral vaccine - Eveliqure Biotechnologies

Next Previous
Drug Profile

Escherichia coli/Shigella oral vaccine - Eveliqure Biotechnologies

Alternative Names: Shigella-ETEC vaccine; ShigETEC

Latest Information Update: 09 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eveliqure Biotechnologies
  • Class Bacterial vaccines; Escherichia coli vaccines; Synthetic vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Diarrhoea
  • No development reported Traveller's diarrhoea

Most Recent Events

  • 09 Aug 2024 Eveliqure Biotechnologies plans a phase II trial for Diarrhoea in USA (Eveliqure Biotechnologies pipeline, July 2024)
  • 28 Mar 2024 No recent reports of development identified for phase-I development in Traveller's-diarrhoea(Prevention) in Hungary (PO, Liquid)
  • 14 Aug 2023 Eveliqure Biotechnologies plans a phase I trial for Diarrhoea (Prevention) in Bangladesh (PO) (NCT05987488)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top